구조모아 (StructureMoa)항암 chemical structure spider web
방문타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-6 · 마지막 9월 2일
현재 선택: 5개 · Data Tier에서 열림
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | zanidatamab (Ziihera, ZW25, zanidatamab-hrii) Jazz Pharmaceuticals / Zymeworks·HER2 (biparatopic) 35 trials·t½ ~7 days | tislelizumab (Tevimbra, BGB-A317, tislelizumab-jsgr) BeOne Medicines·PD-1 213 trials·t½ ~20 days class range | |||
|---|---|---|---|---|---|
Overview Program | Keytruda (pembrolizumab) | Herceptin (trastuzumab) | Tecentriq (atezolizumab) | Ziihera (zanidatamab) | Tevimbra (tislelizumab) |
Overview Company | Merck | Roche / Genentech | Roche / Genentech | Jazz Pharmaceuticals / Zymeworks | BeOne Medicines |
Overview Modality | ANTIBODY | ANTIBODY | ANTIBODY | ANTIBODY | ANTIBODY |
Overview Target | PD-1 | HER2 | PD-L1 | HER2 (biparatopic) | PD-1 |
Overview Indication | Multiple solid tumors | HER2+ breast cancer, HER2+ gastric/GEJ adenocarcinoma | NSCLC, SCLC, HCC, TNBC, urothelial carcinoma, and others | First-line HER2-positive gastric, GEJ, or esophageal adenocarcinoma; previously treated HER2-positive biliary tract cancer | Esophageal squamous cell carcinoma, gastric/GEJ adenocarcinoma, and first-line HER2-positive GEA with zanidatamab and chemotherapy |
Overview Phase | APPROVED | APPROVED | APPROVED | APPROVED | APPROVED |
Overview Status | APPROVED | APPROVED | APPROVED | APPROVED | APPROVED |
Overview Content status | Curated Core | Curated Core | Curated Core | Curated Core | Curated Core |
Overview Data Confidence | Data Confidence · High | Data Confidence · High | Data Confidence · High | Data Confidence · High | Data Confidence · High |
Overview Development Signal | Development Signal · Established | Development Signal · Established | Development Signal · Established | Development Signal · Established | Development Signal · Established |
Overview Approval status | FDA approved | FDA approved | FDA approved | FDA approved | FDA approved |
Positioning Key differentiator | Broad tumor-agnostic biomarker strategies (MSI-H, TMB) | novel bifunctional chelator (2E-C-NETA) for applications in 177 Lu-based TRT | novel agents have been approved in recent years (including systemic pembrolizumab, nogapendekin alfa inbakicept-pmln, N-803), | Dual-epitope binding drives receptor clustering, faster internalization, and stronger signaling blockade than either monoclonal alone. In GEA the label splits IHC 3+ (chemo doublet) from IHC 3+ or 2+/ISH+ (chemo + Tevimbra). | Not a Keytruda substitute. The 2026 GEA label is a HER2-selected triplet with zanidatamab, not a PD-L1-unselected 1L PD-1 row. |
Positioning Known limitation | Loss of antigen presentation (β2M, JAK1/2), alternate checkpoints (TIM-3, LAG-3), and immunosuppressive TME. | resistance to trastuzumab-based targeted therapy and limited intratumoral antibody penetration continue to restrict clinical outcomes | resistance to existing therapies | HER2 heterogeneity, PI3K pathway activation, and bypass RTK signaling. | Antigen-presentation loss, alternate checkpoints, immunosuppressive TME. |
Positioning Development positioning | Global IO standard | — | — | Challenges the ToGA trastuzumab-chemo backbone in 1L HER2+ GEA; still the only HER2 agent with a dedicated BTC indication. | BeOne PD-1 with a China-heavy development history; the US HER2+ GEA triplet is the catalog reason to keep it next to Ziihera, not next to Keytruda's pan-tumor row. |
MoA Mechanism | Pembrolizumab is an IgG4 humanized monoclonal antibody that binds PD-1 on T cells and blocks interaction with PD-L1 and PD-L2, releasing PD-1 pathway-mediated inhibition of the immune response, including antitumor response. | Trastuzumab binds domain IV of HER2, inhibiting ligand-independent HER2 signaling, mediating ADCC via Fcγ receptors, and inducing internalization/degradation of HER2. | Atezolizumab binds PD-L1 and blocks its interaction with PD-1 and B7.1 (CD80), enabling restoration of antitumor T-cell responses without direct PD-1 engagement on T cells. | Simultaneous binding of two non-overlapping HER2 epitopes crosslinks adjacent receptors, causing receptor clustering, internalization, and degradation alongside ADCC and complement activity. | Binds PD-1 on T cells, blocking PD-L1/PD-L2 engagement and restoring antitumor T-cell activity. Fc silencing is intended to avoid macrophage-mediated T-cell clearance. |
MoA Biomarker | PD-L1 CPS/TPS (tumor-specific), MSI-H/dMMR, TMB-H (≥10 mut/Mb), and tumor-type-specific biomarkers per label. | HER2 IHC 3+ or ISH amplified (ASCO/CAP guidelines). | PD-L1 IC/TC scoring in NSCLC and UC; tumor-type-specific thresholds. | GEA: PATHWAY 4B5 IHC and VENTANA Dual ISH. IHC 3+ for chemo doublet; IHC 3+ or IHC 2+/ISH+ when Tevimbra is added. BTC: HER2 IHC 3+. | PD-L1 and tumor type on older labels; HER2 IHC/ISH when given with Ziihera. |
PK/PD Half-life | 22 h | 4 h | 27 h | ~7 days | ~20 days class range |
PK/PD Species | Mouse, Radiographic response, ctDNA clearance in some tumors | Mouse, OS in metastatic BC | Mouse, Human | Cynomolgus monkey, Human, OS and PFS in GEA, ORR and DOR in BTC | OS/PFS, radiographic response |
PK/PD Animal (cat.) | Mouse, In vitro | Mouse, In vitro | Human, Mouse | Human, NHP, In vitro | Human |
PK/PD Experiment | PD | Pharmacokinetic | PD | pd | — |
Toxicology Species | Cynomolgus monkey, Macaque, Mouse, Rat | Mouse, Rat | Cynomolgus monkey, Mouse, Human | Human | — |
Toxicology Major finding | Immune-related AEs | Cardiotoxicity (LVEF decline, CHF risk especially with anthracyclines); infusion reactions; myelosuppression in combos. | Immune-mediated pneumonitis, hepatitis, colitis, endocrinopathies. | Embryo-fetal toxicity warning. Diarrhea, infusion-related reactions, and left ventricular dysfunction require monitoring, as with the HER2 antibody class. | Immune-mediated pneumonitis, colitis, hepatitis, endocrinopathies, and infusion-related reactions. Allogeneic transplant complications are labeled. |
Toxicology CRS | N/A | N/A | N/A | N/A | N/A |
Clinical Safety signal | Immune-related AEs | Cardiotoxicity (LVEF decline, CHF risk especially with anthracyclines); infusion reactions; myelosuppression in combos. | Immune-mediated pneumonitis, hepatitis, colitis, endocrinopathies. | Embryo-fetal toxicity warning. Diarrhea, infusion-related reactions, and left ventricular dysfunction require monitoring, as with the HER2 antibody class. | Immune-mediated pneumonitis, colitis, hepatitis, endocrinopathies, and infusion-related reactions. Allogeneic transplant complications are labeled. |
Clinical Selected reported efficacy | ORR 38% | ORR 91.2% | — | ORR 52% | ORR 87.1% |
Clinical Reported ORR | 38% | 91.2% | — | 52% | 87.1% |
Clinical Reported PFS | — | — | 1.7 | ~5.5 mo | 31.5 |
Clinical Reported OS | — | — | 7.6 | 15.54 | — |
Clinical Result source | ClinicalTrials.gov NCT02444741 | ClinicalTrials.gov NCT02149524 | ClinicalTrials.gov NCT04457778 | HERIZON-BTC-01 (NCT04466891) | ClinicalTrials.gov NCT03209973 |
Clinical Program phase | APPROVED | APPROVED | APPROVED | APPROVED | APPROVED |
Clinical Trial activity | No active/completed counts | No active/completed counts | No active/completed counts | No active/completed counts | — |
Clinical Trial ref | NCT02444741 | NCT02149524 | NCT04457778 | NCT04466891 | NCT03209973 |
Preclinical Animal (cat.) | — | — | Mouse | Unknown | — |
타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-6 · 마지막 9월 2일
현재 선택: 5개 · Data Tier에서 열림
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | zanidatamab (Ziihera, ZW25, zanidatamab-hrii) Jazz Pharmaceuticals / Zymeworks·HER2 (biparatopic) 35 trials·t½ ~7 days | tislelizumab (Tevimbra, BGB-A317, tislelizumab-jsgr) BeOne Medicines·PD-1 213 trials·t½ ~20 days class range | |||
|---|---|---|---|---|---|
Overview Program | Keytruda (pembrolizumab) | Herceptin (trastuzumab) | Tecentriq (atezolizumab) | Ziihera (zanidatamab) | Tevimbra (tislelizumab) |
Overview Company | Merck | Roche / Genentech | Roche / Genentech | Jazz Pharmaceuticals / Zymeworks | BeOne Medicines |
Overview Modality | ANTIBODY | ANTIBODY | ANTIBODY | ANTIBODY | ANTIBODY |
Overview Target | PD-1 | HER2 | PD-L1 | HER2 (biparatopic) | PD-1 |
Overview Indication | Multiple solid tumors | HER2+ breast cancer, HER2+ gastric/GEJ adenocarcinoma | NSCLC, SCLC, HCC, TNBC, urothelial carcinoma, and others | First-line HER2-positive gastric, GEJ, or esophageal adenocarcinoma; previously treated HER2-positive biliary tract cancer | Esophageal squamous cell carcinoma, gastric/GEJ adenocarcinoma, and first-line HER2-positive GEA with zanidatamab and chemotherapy |
Overview Phase | APPROVED | APPROVED | APPROVED | APPROVED | APPROVED |
Overview Status | APPROVED | APPROVED | APPROVED | APPROVED | APPROVED |
Overview Content status | Curated Core | Curated Core | Curated Core | Curated Core | Curated Core |
Overview Data Confidence | Data Confidence · High | Data Confidence · High | Data Confidence · High | Data Confidence · High | Data Confidence · High |
Overview Development Signal | Development Signal · Established | Development Signal · Established | Development Signal · Established | Development Signal · Established | Development Signal · Established |
Overview Approval status | FDA approved | FDA approved | FDA approved | FDA approved | FDA approved |
Positioning Key differentiator | Broad tumor-agnostic biomarker strategies (MSI-H, TMB) | novel bifunctional chelator (2E-C-NETA) for applications in 177 Lu-based TRT | novel agents have been approved in recent years (including systemic pembrolizumab, nogapendekin alfa inbakicept-pmln, N-803), | Dual-epitope binding drives receptor clustering, faster internalization, and stronger signaling blockade than either monoclonal alone. In GEA the label splits IHC 3+ (chemo doublet) from IHC 3+ or 2+/ISH+ (chemo + Tevimbra). | Not a Keytruda substitute. The 2026 GEA label is a HER2-selected triplet with zanidatamab, not a PD-L1-unselected 1L PD-1 row. |
Positioning Known limitation | Loss of antigen presentation (β2M, JAK1/2), alternate checkpoints (TIM-3, LAG-3), and immunosuppressive TME. | resistance to trastuzumab-based targeted therapy and limited intratumoral antibody penetration continue to restrict clinical outcomes | resistance to existing therapies | HER2 heterogeneity, PI3K pathway activation, and bypass RTK signaling. | Antigen-presentation loss, alternate checkpoints, immunosuppressive TME. |
Positioning Development positioning | Global IO standard | — | — | Challenges the ToGA trastuzumab-chemo backbone in 1L HER2+ GEA; still the only HER2 agent with a dedicated BTC indication. | BeOne PD-1 with a China-heavy development history; the US HER2+ GEA triplet is the catalog reason to keep it next to Ziihera, not next to Keytruda's pan-tumor row. |
MoA Mechanism | Pembrolizumab is an IgG4 humanized monoclonal antibody that binds PD-1 on T cells and blocks interaction with PD-L1 and PD-L2, releasing PD-1 pathway-mediated inhibition of the immune response, including antitumor response. | Trastuzumab binds domain IV of HER2, inhibiting ligand-independent HER2 signaling, mediating ADCC via Fcγ receptors, and inducing internalization/degradation of HER2. | Atezolizumab binds PD-L1 and blocks its interaction with PD-1 and B7.1 (CD80), enabling restoration of antitumor T-cell responses without direct PD-1 engagement on T cells. | Simultaneous binding of two non-overlapping HER2 epitopes crosslinks adjacent receptors, causing receptor clustering, internalization, and degradation alongside ADCC and complement activity. | Binds PD-1 on T cells, blocking PD-L1/PD-L2 engagement and restoring antitumor T-cell activity. Fc silencing is intended to avoid macrophage-mediated T-cell clearance. |
MoA Biomarker | PD-L1 CPS/TPS (tumor-specific), MSI-H/dMMR, TMB-H (≥10 mut/Mb), and tumor-type-specific biomarkers per label. | HER2 IHC 3+ or ISH amplified (ASCO/CAP guidelines). | PD-L1 IC/TC scoring in NSCLC and UC; tumor-type-specific thresholds. | GEA: PATHWAY 4B5 IHC and VENTANA Dual ISH. IHC 3+ for chemo doublet; IHC 3+ or IHC 2+/ISH+ when Tevimbra is added. BTC: HER2 IHC 3+. | PD-L1 and tumor type on older labels; HER2 IHC/ISH when given with Ziihera. |
PK/PD Half-life | 22 h | 4 h | 27 h | ~7 days | ~20 days class range |
PK/PD Species | Mouse, Radiographic response, ctDNA clearance in some tumors | Mouse, OS in metastatic BC | Mouse, Human | Cynomolgus monkey, Human, OS and PFS in GEA, ORR and DOR in BTC | OS/PFS, radiographic response |
PK/PD Animal (cat.) | Mouse, In vitro | Mouse, In vitro | Human, Mouse | Human, NHP, In vitro | Human |
PK/PD Experiment | PD | Pharmacokinetic | PD | pd | — |
Toxicology Species | Cynomolgus monkey, Macaque, Mouse, Rat | Mouse, Rat | Cynomolgus monkey, Mouse, Human | Human | — |
Toxicology Major finding | Immune-related AEs | Cardiotoxicity (LVEF decline, CHF risk especially with anthracyclines); infusion reactions; myelosuppression in combos. | Immune-mediated pneumonitis, hepatitis, colitis, endocrinopathies. | Embryo-fetal toxicity warning. Diarrhea, infusion-related reactions, and left ventricular dysfunction require monitoring, as with the HER2 antibody class. | Immune-mediated pneumonitis, colitis, hepatitis, endocrinopathies, and infusion-related reactions. Allogeneic transplant complications are labeled. |
Toxicology CRS | N/A | N/A | N/A | N/A | N/A |
Clinical Safety signal | Immune-related AEs | Cardiotoxicity (LVEF decline, CHF risk especially with anthracyclines); infusion reactions; myelosuppression in combos. | Immune-mediated pneumonitis, hepatitis, colitis, endocrinopathies. | Embryo-fetal toxicity warning. Diarrhea, infusion-related reactions, and left ventricular dysfunction require monitoring, as with the HER2 antibody class. | Immune-mediated pneumonitis, colitis, hepatitis, endocrinopathies, and infusion-related reactions. Allogeneic transplant complications are labeled. |
Clinical Selected reported efficacy | ORR 38% | ORR 91.2% | — | ORR 52% | ORR 87.1% |
Clinical Reported ORR | 38% | 91.2% | — | 52% | 87.1% |
Clinical Reported PFS | — | — | 1.7 | ~5.5 mo | 31.5 |
Clinical Reported OS | — | — | 7.6 | 15.54 | — |
Clinical Result source | ClinicalTrials.gov NCT02444741 | ClinicalTrials.gov NCT02149524 | ClinicalTrials.gov NCT04457778 | HERIZON-BTC-01 (NCT04466891) | ClinicalTrials.gov NCT03209973 |
Clinical Program phase | APPROVED | APPROVED | APPROVED | APPROVED | APPROVED |
Clinical Trial activity | No active/completed counts | No active/completed counts | No active/completed counts | No active/completed counts | — |
Clinical Trial ref | NCT02444741 | NCT02149524 | NCT04457778 | NCT04466891 | NCT03209973 |
Preclinical Animal (cat.) | — | — | Mouse | Unknown | — |
추천 비교
추천 비교